Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation |
| |
| Authors: | Deegens, Jeroen K. J. Wetzels, Jack F. M. |
| |
| Affiliation: | Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands |
| |
| Abstract: | | Introduction | Focal segmental glomerulosclerosis (FSGS) can recur after renaltransplantation and is associated with a reduced graft survival.In the case of recurrent FSGS, treatment with plasma exchange(PE) results in a remission of proteinuria in up to 85% of patients,especially if started shortly after the onset of recurrence[1,2]. However, many patients require repeated courses of PEbecause of frequent relapses [1,3]. Recently, a 7-year-old boywith recurrent FSGS after renal transplantation responded torituximab, a monoclonal anti-CD20 antibody, that was administeredfor a transplantation-related lymphoma [4]. Following this report,several other cases with recurrent FSGS after renal transplantationwere published, showing varying degrees of success after treatmentwith rituximab [5]. We describe
| |
| Keywords: | focal segmental glomerulosclerosis recurrence renal transplantation rituximab |
| 本文献已被 Oxford 等数据库收录！ |
|
